hCCR8(2)

Fig1. Expression characterization of CCR8 humanized mouse. 

(A) Human CCR8 expression on activated splenic CD4+, CD8+ and Treg cells upon anti-mCD3/mCD28 stimulation in hCCR8 mice; (B) Statistics of T cell populations in hCCR8 mice.

Fig2. The anti-hCCR8 therapeutic antibody shows potent antitumor efficacy in hCCR8 mice. 

(A) and (B) in vivo antitumor response of anti-hCCR8 in hCCR8 mice bearing MC38 tumor.

Fig3. In vivo antitumor responses of anti-hCCR8 alone or in combination with anti-PD-1 in hCCR8 knockin mice engrafted with MC38 tumor. 

(A) Mean tumor growth curves upon treatment; (B) Individual tumor growth curves upon treatment.

Fig4. In vivo efficacy study in CCR8 humanized mice grafted with MC38 tumor model. JTX-1811 can inhibit the growth of MC38 xenografts (A) without significant effect on the body weight of CCR8 humanized mice (B).(provided by partner)